A Preclinical Humanized Chimeric Model To Investigate Novel Therapeutic Strategies Against Breast Cancer Bone Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$696,362.00
Summary
Using the humanized in-vivo model presented, researchers are in a unique position to develop and evaluate novel therapeutic strategies against breast cancer bone metastasis at multiple intervention points from the primary tumour to bone metastasis. This model makes it possible to study anti-cancer and anti-resorptive effects of human-specific drugs such as the monoclonal antibody Denosumab. The model eventually may help to decrease morbidity and mortality of breast cancer patients.
A Novel Role For CBF? As A Regulator Of Breast Cancer
Funder
National Health and Medical Research Council
Funding Amount
$682,415.00
Summary
Whole genome sequencing studies of human breast tumours identified a handful of common significantly mutated genes, all previously linked to breast cancer, except one, CBF?. Preliminary data from our lab now show that CBF? may be a new regulator of human breast cancer and metastasis. Using mice with altered CBF? levels, breast cancer models and human patient cohorts, this study aims to identify a novel role for CBF? as a new regulator of human breast cancer and potential therapeutic target.
Identification Of Genes Causing Medulloblastoma By Transposon Mutagenesis.
Funder
National Health and Medical Research Council
Funding Amount
$621,997.00
Summary
Brain tumours are the most common cause of cancer-related death in children and the tumour medulloblastoma is the most frequent. There is a need to develop new therapeutic approaches to treating medulloblastoma through the development of new drugs to directly target the tumour. This research has identified new genes that are good candidates as drug targets for treating medulloblastoma.